Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese

Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program

Javier A. Valle, Colin I. O'Donnell, Ehrin J. Armstrong, Steven M. Bradley, Thomas M. Maddox, P. Michael Ho

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

BACKGROUND: Stigma against the obese is well described in health care and may contribute to disparities in medical decision-making. It is unknown whether similar disparity exists for obese patients in cardiovascular care. We evaluated the association between body mass index (BMI) and prescription of guideline-recommended medications in patients undergoing elective percutaneous coronary intervention.

METHODS AND RESULTS: Using data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program, we identified patients undergoing elective percutaneous coronary intervention from 2007 to 2012, stratifying them by category of BMI. We described rates of prescription for class I guideline recommended medications for each BMI category (normal, overweight, and obese). Multivariable logistic regression assessed the association between BMI category and medication prescription. Seventeen thousand thirty-seven patients were identified, with 35.3% having overweight BMI, and 50.8% obese BMI. Obese patients were more likely than normal BMI patients to be prescribed β-blockers (OR 1.34), statins (OR 1.39), or ACE/ARB (odds ratio [OR] 1.52; all significant) when indicated. Overweight patients were more likely than normal BMI patients to be prescribed statins (OR 1.29) and angiotensin-converting enzymes/angiotensin II receptor blockers (OR 1.41) when indicated. There was no association between BMI category and prescription of anticoagulants.

CONCLUSIONS: Over 85% of patients undergoing elective percutaneous coronary intervention in the Veterans Affairs are overweight or obese. Rates of guideline-indicated medication prescription were <70% among all patients, and across BMI categories, with an association between increased BMI and greater use of guideline-recommended medications. Our findings offer a possible contribution to the obesity paradox seen in many cardiovascular conditions.

Original languageEnglish (US)
JournalJournal of the American Heart Association
Volume5
Issue number5
DOIs
StatePublished - May 16 2016

Fingerprint

Veterans
Body Mass Index
Cardiovascular Diseases
Guidelines
Prescriptions
Odds Ratio
Percutaneous Coronary Intervention
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin Receptor Antagonists
Peptidyl-Dipeptidase A
Anticoagulants
Obesity
Logistic Models
Delivery of Health Care

Keywords

  • cardiovascular disease
  • medication therapy
  • obesity
  • prevention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese : Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. / Valle, Javier A.; O'Donnell, Colin I.; Armstrong, Ehrin J.; Bradley, Steven M.; Maddox, Thomas M.; Ho, P. Michael.

In: Journal of the American Heart Association, Vol. 5, No. 5, 16.05.2016.

Research output: Contribution to journalArticle

Valle, Javier A. ; O'Donnell, Colin I. ; Armstrong, Ehrin J. ; Bradley, Steven M. ; Maddox, Thomas M. ; Ho, P. Michael. / Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese : Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program. In: Journal of the American Heart Association. 2016 ; Vol. 5, No. 5.
@article{7ed7c191a2f841e8aa78acaa275ad9e5,
title = "Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program",
abstract = "BACKGROUND: Stigma against the obese is well described in health care and may contribute to disparities in medical decision-making. It is unknown whether similar disparity exists for obese patients in cardiovascular care. We evaluated the association between body mass index (BMI) and prescription of guideline-recommended medications in patients undergoing elective percutaneous coronary intervention.METHODS AND RESULTS: Using data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program, we identified patients undergoing elective percutaneous coronary intervention from 2007 to 2012, stratifying them by category of BMI. We described rates of prescription for class I guideline recommended medications for each BMI category (normal, overweight, and obese). Multivariable logistic regression assessed the association between BMI category and medication prescription. Seventeen thousand thirty-seven patients were identified, with 35.3{\%} having overweight BMI, and 50.8{\%} obese BMI. Obese patients were more likely than normal BMI patients to be prescribed β-blockers (OR 1.34), statins (OR 1.39), or ACE/ARB (odds ratio [OR] 1.52; all significant) when indicated. Overweight patients were more likely than normal BMI patients to be prescribed statins (OR 1.29) and angiotensin-converting enzymes/angiotensin II receptor blockers (OR 1.41) when indicated. There was no association between BMI category and prescription of anticoagulants.CONCLUSIONS: Over 85{\%} of patients undergoing elective percutaneous coronary intervention in the Veterans Affairs are overweight or obese. Rates of guideline-indicated medication prescription were <70{\%} among all patients, and across BMI categories, with an association between increased BMI and greater use of guideline-recommended medications. Our findings offer a possible contribution to the obesity paradox seen in many cardiovascular conditions.",
keywords = "cardiovascular disease, medication therapy, obesity, prevention",
author = "Valle, {Javier A.} and O'Donnell, {Colin I.} and Armstrong, {Ehrin J.} and Bradley, {Steven M.} and Maddox, {Thomas M.} and Ho, {P. Michael}",
year = "2016",
month = "5",
day = "16",
doi = "10.1161/JAHA.115.003120",
language = "English (US)",
volume = "5",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Guideline Recommended Medical Therapy for Cardiovascular Diseases in the Obese

T2 - Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) Program

AU - Valle, Javier A.

AU - O'Donnell, Colin I.

AU - Armstrong, Ehrin J.

AU - Bradley, Steven M.

AU - Maddox, Thomas M.

AU - Ho, P. Michael

PY - 2016/5/16

Y1 - 2016/5/16

N2 - BACKGROUND: Stigma against the obese is well described in health care and may contribute to disparities in medical decision-making. It is unknown whether similar disparity exists for obese patients in cardiovascular care. We evaluated the association between body mass index (BMI) and prescription of guideline-recommended medications in patients undergoing elective percutaneous coronary intervention.METHODS AND RESULTS: Using data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program, we identified patients undergoing elective percutaneous coronary intervention from 2007 to 2012, stratifying them by category of BMI. We described rates of prescription for class I guideline recommended medications for each BMI category (normal, overweight, and obese). Multivariable logistic regression assessed the association between BMI category and medication prescription. Seventeen thousand thirty-seven patients were identified, with 35.3% having overweight BMI, and 50.8% obese BMI. Obese patients were more likely than normal BMI patients to be prescribed β-blockers (OR 1.34), statins (OR 1.39), or ACE/ARB (odds ratio [OR] 1.52; all significant) when indicated. Overweight patients were more likely than normal BMI patients to be prescribed statins (OR 1.29) and angiotensin-converting enzymes/angiotensin II receptor blockers (OR 1.41) when indicated. There was no association between BMI category and prescription of anticoagulants.CONCLUSIONS: Over 85% of patients undergoing elective percutaneous coronary intervention in the Veterans Affairs are overweight or obese. Rates of guideline-indicated medication prescription were <70% among all patients, and across BMI categories, with an association between increased BMI and greater use of guideline-recommended medications. Our findings offer a possible contribution to the obesity paradox seen in many cardiovascular conditions.

AB - BACKGROUND: Stigma against the obese is well described in health care and may contribute to disparities in medical decision-making. It is unknown whether similar disparity exists for obese patients in cardiovascular care. We evaluated the association between body mass index (BMI) and prescription of guideline-recommended medications in patients undergoing elective percutaneous coronary intervention.METHODS AND RESULTS: Using data from the Veterans Affairs Clinical Assessment, Reporting, and Tracking System Program, we identified patients undergoing elective percutaneous coronary intervention from 2007 to 2012, stratifying them by category of BMI. We described rates of prescription for class I guideline recommended medications for each BMI category (normal, overweight, and obese). Multivariable logistic regression assessed the association between BMI category and medication prescription. Seventeen thousand thirty-seven patients were identified, with 35.3% having overweight BMI, and 50.8% obese BMI. Obese patients were more likely than normal BMI patients to be prescribed β-blockers (OR 1.34), statins (OR 1.39), or ACE/ARB (odds ratio [OR] 1.52; all significant) when indicated. Overweight patients were more likely than normal BMI patients to be prescribed statins (OR 1.29) and angiotensin-converting enzymes/angiotensin II receptor blockers (OR 1.41) when indicated. There was no association between BMI category and prescription of anticoagulants.CONCLUSIONS: Over 85% of patients undergoing elective percutaneous coronary intervention in the Veterans Affairs are overweight or obese. Rates of guideline-indicated medication prescription were <70% among all patients, and across BMI categories, with an association between increased BMI and greater use of guideline-recommended medications. Our findings offer a possible contribution to the obesity paradox seen in many cardiovascular conditions.

KW - cardiovascular disease

KW - medication therapy

KW - obesity

KW - prevention

UR - http://www.scopus.com/inward/record.url?scp=85039561818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039561818&partnerID=8YFLogxK

U2 - 10.1161/JAHA.115.003120

DO - 10.1161/JAHA.115.003120

M3 - Article

VL - 5

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 5

ER -